Summary
BSGM Chart
BioSig Stock Surges Following Share Exchange Deal With Streamex
BSGM merges with Streamex to enter the blockchain space, aiming to revolutionize commodity tokenization and expand its footprint in digital asset markets.
Biosig Technologies (BSGM) Upgraded to Buy: What Does It Mean for the Stock?
Biosig Technologies (BSGM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BioSig Technologies Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| RF Rekah Franca Catalyst Funds Management Pty Ltd. | 13,500 | $15,255 | $12,387.6 | -$2,867.4 | -18.8% |
| SM Sharon Medina INTEGRITY WEALTH ADVISORS Inc. | 15,743 | $43,390.25 | $96,032.3 | $52,642.05 | 121.32% |
| PIL PFG Investments LLC PFG Investments LLC | 130,691 | $343,882.14 | $119,922.06 | -$223,960.08 | -65.13% |
 Jessica Riley Hale GC Wealth Management RIA, LLC | 57,435 | $64,902 | $52,725.33 | -$12,176.67 | -18.76% |
 Jefferson H. West Legacy Investment Solutions LLC | 6.84M | $28.47M | $41.72M | $13.25M | 46.52% |
BioSig Technologies Inc. (BSGM) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
BioSig Technologies Inc. Profile
| Health Care Technology Industry | Healthcare Sector | Anthony Amato CEO | NASDAQ (CM) Exchange | 09073N300 CUSIP |
| US Country | 5 Employees | - Last Dividend | 2 Feb 2024 Last Split | 30 Oct 2014 IPO Date |
Overview
BioSig Technologies, Inc., along with its subsidiaries, operates as a medical device company focused on commercializing its unique digital signal processing technology platform designed to improve the treatment of cardiovascular arrhythmias. Established in 2009 and headquartered in Westport, Connecticut, the company has specialized its efforts towards the development and commercialization of the PURE EP system. This innovative platform aims to enhance the quality of life for patients suffering from arrhythmias by simplifying and improving the efficiency of catheter ablation procedures. Furthermore, BioSig Technologies is also involved in collaborative research to explore novel therapies for sympathetic nervous system diseases and is working on integrating AI and machine learning capabilities into their systems through strategic partnerships with leading research institutions like the University of Minnesota and the Mayo Foundation for Medical Education and Research.
Products and Services
- PURE EP System
The PURE EP system stands as BioSig Technologies’ flagship offering, combining advanced hardware with sophisticated software to tackle the challenges associated with signal acquisition during cardiac procedures. This platform is engineered to allow electrophysiologists to view and analyze cardiac signals in real-time, enhancing the diagnostic information available during catheter ablation procedures. The goal of the PURE EP system is to overcome the limitations that have traditionally hampered these procedures, improving outcomes for patients with arrhythmias. By focusing on the clarity and accuracy of intracardiac signals, it aims to facilitate more efficient and effective treatments.
- Research and Development
Aside from its key product, BioSig Technologies is deeply invested in research and development efforts to push the boundaries of medical technology further. Through its research agreement with the University of Minnesota, the company is exploring innovative therapies aimed at treating diseases of the sympathetic nervous system. Additionally, its strategic collaboration with the Mayo Foundation is focused on the development of AI-and machine learning-powered software solutions tailored for the PURE EP systems. These initiatives highlight BioSig Technologies’ commitment to leveraging cutting-edge technology to enhance the functionality and effectiveness of its products, ultimately aiming to improve patient care in the cardiovascular domain.
